169 related articles for article (PubMed ID: 11073755)
1. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Dubé MP; Sprecher D; Henry WK; Aberg JA; Torriani FJ; Hodis HN; Schouten J; Levin J; Myers G; Zackin R; Nevin T; Currier JS;
Clin Infect Dis; 2000 Nov; 31(5):1216-24. PubMed ID: 11073755
[TBL] [Abstract][Full Text] [Related]
2. Lipid abnormalities.
Dube M; Fenton M
Clin Infect Dis; 2003 Apr; 36(Suppl 2):S79-83. PubMed ID: 12652375
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
Dubé MP; Stein JH; Aberg JA; Fichtenbaum CJ; Gerber JG; Tashima KT; Henry WK; Currier JS; Sprecher D; Glesby MJ; ;
Clin Infect Dis; 2003 Sep; 37(5):613-27. PubMed ID: 12942391
[No Abstract] [Full Text] [Related]
4. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
Aberg JA
Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
[TBL] [Abstract][Full Text] [Related]
5. The evaluation and management of dyslipidemia in HIV-infected patients.
Fichtenbaum CJ
AIDS Clin Care; 2001 Dec; 13(12):113-7, 120. PubMed ID: 11769116
[No Abstract] [Full Text] [Related]
6. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
8. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Grover SA; Coupal L; Gilmore N; Mukherjee J
Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
[TBL] [Abstract][Full Text] [Related]
9. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Dubé MP
Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
[TBL] [Abstract][Full Text] [Related]
10. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
12. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
Cooper CL; Mills E; Angel JB
AIDS; 2007 Jan; 21(1):71-6. PubMed ID: 17148970
[TBL] [Abstract][Full Text] [Related]
13. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk among HIV-positive patients on antiretroviral therapy.
Aberg JA
J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635
[TBL] [Abstract][Full Text] [Related]
15. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
Novak RM; Chen L; MacArthur RD; Baxter JD; Huppler Hullsiek K; Peng G; Xiang Y; Henely C; Schmetter B; Uy J; van den Berg-Wolf M; Kozal M;
Clin Infect Dis; 2005 Feb; 40(3):468-74. PubMed ID: 15668873
[TBL] [Abstract][Full Text] [Related]
17. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
Manfredi R
Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
[TBL] [Abstract][Full Text] [Related]
18. HIV protease inhibitors and dyslipidemia.
Clotet B; Negredo E
AIDS Rev; 2003; 5(1):19-24. PubMed ID: 12875104
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
Magen E; Elbirt D; Sthoeger Z
Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
